![(2S)-1-[(2S)-2-[[(1S)-1-(butoxycarbonyl)-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid](https://veeprho.com/wp-content/uploads/2022/07/Enalapril-EP-Impurity-F-free-base--sqr.png "(2S)-1-[(2S)-2-[[(1S)-1-(butoxycarbonyl)-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid")
Lagerstandorte
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Vorbehaltlich Verfügbarkeit
Dokumentation
Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.
76391-34-9(2S)-1-[(2S)-2-[[(1S)-1-(butoxycarbonyl)-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
● Auf Lager
| Katalog-Nr.:: | VE006628 |
|---|---|
| CAS-Nr.:: | 76391-34-9 |
| Summenformel:: | C22H32N2O5 |
| Molare Masse:: | 404.50 g/mol |
Zusätzliche Informationen zu CAS 76391-34-9
Parent drug
EnalaprilIUPAC-Name
(2S)-1-(2-((1-butoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)pyrrolidine-2-carboxylic acidPharmakopöe-Synonyme
N/AOther Synonyms
Enalapril Butyl Ester Analog; ((S)-1-Butoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-prolineSMILES
O=C([C@H]1N(C([C@@H](N[C@H](C(OCCCC)=O)CCC2=CC=CC=C2)C)=O)CCC1)OInChI
InChI=1S/C22H32N2O5/c1-3-4-15-29-22(28)18(13-12-17-9-6-5-7-10-17)23-16(2)20(25)24-14-8-11-19(24)21(26)27/h5-7,9-10,16,18-19,23H,3-4,8,11-15H2,1-2H3,(H,26,27)/t16-,18-,19-/m0/s1Beschreibung
Enalapril EP Impurity F (Free Base ) is a well-characterized reference material that meets stringent regulatory standards set by USP, EMA, JP, and BP. It plays a key role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Enalapril. Also known as Enalapril Butyl Ester Analog, it is a prodrug that is hydrolyzed after absorption to form the active angiotensin-converting enzyme Enalaprilat. It is administered orally. It decreases blood pressure by lowering peripheral resistance without increasing heart rate. It is well tolerated and safe.
References
Sax, Paul E., et al. “Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380–1490): A Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial.†The Lancet, vol. 390, no. 10107, Nov. 2017, pp. 2073–82, https://doi.org/10.1016/s0140-6736(17)32340-1. Bang, Lynne M., and Lesley J. Scott. “Emtricitabine.†Drugs, vol. 63, no. 22, 2003, pp. 2413–24, https://doi.org/10.2165/00003495-200363220-00003.Angebot anfordern
„*“ zeigt erforderliche Felder an
Other products related to Enalapril impurities
![(2S)-1-[(2S)-2-[[(1S)-1-(butoxycarbonyl)-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid](https://veeprho.com/wp-content/uploads/2026/01/Enalapril-Maleate-Working-Standard-Secondary-Reference-Standard-76095-16-4-VE0026931.png "(2S)-1-[(2S)-2-[[(1S)-1-(butoxycarbonyl)-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid")
Enalapril / Enalapril Maleate
![(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]propanoic Acid Ethyl Ester Hydrochloride](https://veeprho.com/wp-content/uploads/2025/01/VE0022781-2S-2-1S-1-Ethoxycarbonyl-3-phenylpropyl-amino-propanoic-Acid-Ethyl-Ester-Hydrochloride.png "(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]propanoic Acid Ethyl Ester Hydrochloride")
Enalapril
